公司资料
Orphazyme 股价、新闻与催化剂
- 股票代码:
- ORPH
- 交易所:
- NASDAQ
- 行业:
- Biopharma
- 所在地:
- Denmark and traded in the U
股价为何变动
Current closing-price context is not available for ORPH.
公司概览
业务概览
Orphazyme was a CNS-focused biotechnology company built around heat-shock protein biology and rare disease neuroscience programs. Its narrative was centered on difficult neurologic conditions where even modest clinical signals could matter, but the company ultimately became a historical small-cap biotech name.
所在地与行业分类
Orphazyme was based in Denmark and traded in the U.S. as an ADR, giving it a cross-border biotechnology profile. It belonged to the rare-disease and neuroscience development segment rather than commercial pharma.
商业模式特征
The business model was defined by clinical development, regulatory uncertainty, and the challenge of financing a narrow pipeline. Investors historically watched proof-of-concept data and whether the company could translate biology into an approvable asset.
生物医药行业定位
Orphazyme sits in the historical bucket of high-risk CNS biotech names. It is best understood as a cautionary example of how difficult rare-disease neuroscience development can be for a small public company.
未来催化剂
- Orphazyme is a legacy / closeout story now, so the catalysts are any remaining resolution update rather than a pipeline event. The market is focused on residual value.
近期新闻
相似股票
商业成熟度、治疗领域或催化剂模式相近的同行公司。